Search

Your search keyword '"Allergan Inc. -- Product information -- 00004163"' showing total 8 results
Start Over Descriptor "Allergan Inc. -- Product information -- 00004163"
8 results on '"Allergan Inc. -- Product information -- 00004163"'

1. Allergan's AMO Array Receives U.S. Marketing Approval

Subjects
Allergan Inc. -- Product information -- 00004163, Surgical equipment and supplies industry -- Product information, Business, Business, international
Abstract

IRVINE, Calif.--(BW HealthWire)--Sept. 8, 1997--Allergan, Inc. (NYSE:AGN) today announced it has received approval from the Food and Drug Administration (FDA) to market the AMO(r)Array(r) Multifocal Silicone Posterior Chamber Intraocular Lens [...]

Published
1997

2. Allergan's Tazorac receives U.S. marketing approval for the once daily treatment of stable plaque psoriasis and facial acne

Subjects
Allergan Inc. -- Product information -- 00004163, Pharmaceutical industry -- Product information, Business, Business, international
Abstract

IRVINE, Calif.--(BW HealthWire)--June 16, 1997--Allergan, Inc. (NYSE: AGN) today announced that it has received approval from the Food and Drug Administration (FDA) to market Tazorac(tm) (tazarotene topical gel) 0.05% and [...]

Published
1997

3. ALLERGAN'S ALPHAGAN RECEIVES U.K. APPROVAL

Subjects
Allergan Inc. -- Product information -- 00004163, Pharmaceutical industry -- Product information, Business, Business, international
Abstract

IRVINE, Calif.--(BW HealthWire)--March 24, 1997--Allergan, Inc. (NYSE:AGN) today announced that it has received clearance from the Medicines Control Agency to market ALPHAGAN(r)(brimonidine) in the United Kingdom for the treatment of [...]

Published
1997

4. Allergan's Ocuflox receives marketing approval for treating corneal ulcers

Subjects
Allergan Inc. -- Product information -- 00004163, Pharmaceutical industry -- Product information, Business, Business, international
Abstract

IRVINE, Calif.--(BUSINESS WIRE)--May 28, 1996--Allergan Inc. (NYSE:AGN) Tuesday announced that it has received clearance from the Food and Drug Administration to market Ocuflox(R) (ofloxacin ophthalmic solution) 0.3% in the United [...]

Published
1996

5. INVESTIGATORS PRESENT PHASE 1-2A DATA AT ASCO ON ALLERGAN-LIGAND FIRST COMPOUND, LGD1057 (ALRT1057) PHASE 2B EFFICACY TRIALS INITIATED

Subjects
Ligand Pharmaceuticals Inc. -- Product information -- 00255141, Allergan Inc. -- Product information -- 00004163, Pharmaceutical industry -- Product information, Antineoplastic agents -- Testing, Business, News, opinion and commentary, Memorial Sloan-Kettering Cancer Center -- Research
Abstract

SAN DIEGO and IRVINE, Calif., May 23 /PRNewswire/ -- Investigators from Memorial Sloan-Kettering Cancer Center (MSKCC) reported results of their Phase 1-2a single daily dose trial with Oral LGD1057 (ALRT1057), [...]

Published
1995

6. TECHNOLOGY LENDS A HAND

Author

Joyce, Romy

Subjects
M.D. Formulations -- Product information, Allergan Inc. -- Product information -- 00004163, Health products industry -- Product information, Cosmetics industry -- Product information, Business, Fashion, accessories and textiles industries, Retail industry
Published
1998

7. Latest Japanese approvals

Subjects
Japan -- Social policy, Rhone-Poulenc Rorer Inc. -- Product information -- 00307477, Allergan Inc. -- Product information -- 00004163, Drug approval -- Management, Antineoplastic agents -- Health aspects, Pharmaceutical industry -- Product information, Spasms -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Taxotere (Medication) -- Health aspects, Botox (Medication) -- Health aspects
Published
1996

8. Allergan's Acular NDA plans

Subjects
Allergan Inc. -- Product information -- 00004163, Pharmaceutical industry -- Product information, Ophthalmic drugs -- Health aspects, Eye, Business, Pharmaceuticals and cosmetics industries, Acular (Medication) -- Health aspects
Published
1996

Catalog

Books, media, physical & digital resources
See catalog results